Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia

Cytotherapy

Volumn 16, Issue 12, 2014, Pages 1733-1738

  Dubský, Michal ^a   Jirkovská, Alexandra ^a   Bem, Robert ^a   Fejfarová, Vladimíra ^a   Pagacová, Libuse ^a   Nemcová, Andrea ^a   Sixta, Bedrich ^a   Chlupac, Jaroslav ^a   Peregrin, Jan H ^a   Syková, Eva ^b   Jude, Edward B ^c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Critical limb ischemia; Percutaneous transluminal angioplasty; Stem cell therapy

Indexed keywords

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETIC FOOT; FALSE ANEURYSM; FEMALE; FOOT AMPUTATION; HEMATOMA; HUMAN; INTERMETHOD COMPARISON; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; OXYGEN TISSUE LEVEL; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE HEMORRHAGE; PRESSURE MEASUREMENT; TREATMENT OUTCOME; ULCER HEALING; WOUND DEHISCENCE; WOUND HEALING; AGED; ANGIOPLASTY; AUTOGRAFT; BIOLOGICAL THERAPY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; STEM CELL TRANSPLANTATION;

AGED; ANGIOPLASTY; AUTOGRAFTS; CELL- AND TISSUE-BASED THERAPY; DIABETIC FOOT; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; STEM CELL TRANSPLANTATION;

EID: 84911888360     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.08.010     Document Type: Article

References (34)

1. Bradbury A.W., Adam D.J., Bell J., Forbes J.F., Fowkes F.G., Gillespie I., et al. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 2010, 14:1-210. iii-iv.
2. Schaper N.C., Andros G., Apelqvist J., Bakker K., Lammer J., Lepantalo M., et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2012, 28(Suppl. 1):218-224.
3. Fadini G.P., Agostini C., Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010, 209:10-17.
4. Jude E.B., Eleftheriadou I., Tentolouris N. Peripheral arterial disease in diabetes-a review. Diabet Med 2010, 27:4-14.
5. Hinchliffe R.J., Andros G., Apelqvist J., Bakker K., Friederichs S., Lammer J., et al. Asystematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes/metabolism research and reviews 2012, 28(Suppl. 1):179-217.
6. Lepantalo M., Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg 1996, 11:153-157.
7. Soderstrom M.I., Arvela E.M., Korhonen M., Halmesmäki K.H., Albäck A.N., Biancari F., et al. Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg 2010, 252:765-773.
8. Collinson D.J., Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur J Vasc Endovasc Surg 2004, 28:9-23.
9. Hankey G.J., Norman P.E., Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 2006, 295:547-553.
10. Awad O., Dedkov E.I., Jiao C., Bloomer S., Tomanek R.J., Schatteman G.C. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arteriosclerosis, thrombosis, and vascular biology 2006, 26:758-764.
11. Timmermans F., Van Hauwermeiren F., De Smedt M., Raedt R., Plasschaert F., De Buyzere M.L., et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thrombo Vasc Biol 2007, 27:1572-1579.
12. Matoba S., Matsubara H. Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation. Curr Pharm Des 2009, 15:2769-2777.
13. Amann B., Luedemann C., Ratei R., Schmidt-Lucke J.A. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant 2009, 18:371-380.
14. Huang P.P., Yang X.F., Li S.Z., Wen J.C., Zhang Y., Han Z.C. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007, 98:1335-1342.
15. Powell R.J., Marston W.A., Berceli S.A., Guzman R., Henry T.D., Longcore A.T., et al. Cellular therapy with ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI Trial. Mol Ther 2012, 20:1280-1286.
16. Prochazka V., Gumulec J., Jaluvka F., Salounová D., Jonszta T., Czerný D., et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010, 19:1413-1424.
17. Attanasio S., Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 2009, 17:115-120.
18. Lawall H., Bramlage P., Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010, 103:696-709.
19. Bura A., Planat-Benard V., Bourin P., Silvestre J.S., Gross F., Grolleau J.L., et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014, 16:245-257.
20. Dubsky M., Jirkovska A., Bem R., Fejfarova V., Pagacova L., Sixta B., et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev 2013, 29:369-376.
21. Dubsky M, Jirkovska A, Bem R, Fejfarova V, Varga M, Kolesar L, etal. Role of serum levels of angiogenic cytokines in assessment of angiogenesis after stem cell therapy of diabetic patients with critical limb ischemia [published online ahead of print October 21, 2013]. Cell Transplant.
22. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):S1-75.
23. Schaper N.C. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004, 20(Suppl. 1):S90-S95.
24. Graziani L., Silvestro A., Bertone V., Manara E., Andreini R., Sigala A., et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007, 33:453-460.
25. Armstrong D.G., Lavery L.A., Harkless L.B. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21:855-859.
26. Sykova E., Homola A., Mazanec R., Lachmann H., Konrádová S.L., Kobylka P., et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006, 15:675-687.
27. Teraa M., Sprengers R.W., van der Graaf Y., Peters C.E., Moll F.L., Verhaar M.C. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013, 258:922-929.
28. Matoba S., Tatsumi T., Murohara T., Imaizumi T., Katsuda Y., Ito M., et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation (TACT) trial) in patients with chronic limb ischemia. Am Heart J 2008, 156:1010-1018.
29. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
30. Peregrin J.H., Koznar B., Kovac J., Lastovicková J., Novotný J., Vedlich D., et al. PTA of infrapopliteal arteries: long-term clinical follow-up and analysis of factors influencing clinical outcome. Cardiovasc Intervent Radiol 2010, 33:720-725.
31. Walter D.H., Krankenberg H., Balzer J.O., Kalka C., Baumgartner I., Schlüter M., et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011, 4:26-37.
32. Al Mheid I., Quyyumi A.A. Cell therapy in peripheral arterial disease. Angiology 2008, 59:705-716.
33. Redlich U., Xiong Y.Y., Pech M., Tautenhahn J., Halloul Z., Lobmann R., et al. Superiority of transcutaneous oxygen tension measurements in predicting limb salvage after below-the-knee angioplasty: a prospective trial in diabetic patients with critical limb ischemia. Cardiovasc Intervent Radiol 2011, 34:271-279.
34. Hart C.A., Tsui J., Khanna A., Abraham D.J., Baker D.M. Stem cells of the lower limb: their role and potential in management of critical limb ischemia. Exp Biol Med (Maywood) 2013, 238:1118-1126.